Viatris Stock Today
| VTRS Stock | USD 9.10 0.12 1.34% |
PerformanceVery Weak
| Odds Of DistressAbove Average
|
Viatris is selling for under 9.10 as of the 16th of March 2025; that is 1.34 percent increase since the beginning of the trading day. The stock's lowest day price was 8.99. Viatris has more than 60 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Note, on January 26, 2021, Representative Mo Brooks of US Congress acquired under $15k worth of Viatris's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2020 | Category Healthcare | Classification Health Care |
The company operates in four segments Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Viatris operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 1.19 B outstanding shares of which 27.39 M shares are at this time shorted by private and institutional investors with about 2.22 trading days to cover. More on Viatris
Moving together with Viatris Stock
Moving against Viatris Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Viatris Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Scott Smith | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Pharmaceutical, SP 500 Index, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsViatris can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Viatris' financial leverage. It provides some insight into what part of Viatris' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Viatris (VTRS) is traded on NASDAQ Exchange in USA. It is located in Robert J. Coury Global Center, Canonsburg, PA, United States, 15317 and employs 32,000 people. Viatris is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.86 B. Viatris conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.19 B outstanding shares of which 27.39 M shares are at this time shorted by private and institutional investors with about 2.22 trading days to cover.
Viatris currently holds about 741.9 M in cash with 2.3 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Check Viatris Probability Of Bankruptcy
Ownership AllocationViatris shows a total of 1.19 Billion outstanding shares. The majority of Viatris outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Viatris to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Viatris. Please pay attention to any change in the institutional holdings of Viatris as this could imply that something significant has changed or is about to change at the company. On January 26, 2021, Representative Mo Brooks of US Congress acquired under $15k worth of Viatris's common stock.
Check Viatris Ownership Details
Viatris Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 15.4 M | |
| Camber Capital Management Llc | 2024-12-31 | 15 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 14.8 M | |
| Northern Trust Corp | 2024-12-31 | 12.3 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 11.9 M | |
| Australiansuper Pty Ltd | 2024-12-31 | 11.6 M | |
| Norges Bank | 2024-12-31 | 11.5 M | |
| Bank Of New York Mellon Corp | 2024-12-31 | 10.7 M | |
| Citadel Advisors Llc | 2024-12-31 | 10 M | |
| Vanguard Group Inc | 2024-12-31 | 142.1 M | |
| Blackrock Inc | 2024-12-31 | 94.1 M |
Viatris Historical Income Statement
Viatris Stock Against Markets
Viatris Corporate Management
| Melissa Trombetta | Head Relations | Profile | |
| Andrew Enrietti | Chief Officer | Profile | |
| Theodora Mistras | Chief Officer | Profile | |
| David Bayles | Chief Officer | Profile | |
| Sanjeev Sethi | Chief Officer | Profile | |
| Ramkumar Rayapureddy | Chief Officer | Profile |
Additional Tools for Viatris Stock Analysis
When running Viatris' price analysis, check to measure Viatris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viatris is operating at the current time. Most of Viatris' value examination focuses on studying past and present price action to predict the probability of Viatris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viatris' price. Additionally, you may evaluate how the addition of Viatris to your portfolios can decrease your overall portfolio volatility.